Skip to main content
Log in

Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases

  • Research Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of the present study is to develop a quantitative turboflow LC-MS/MS method that can be used for rapid quantification of LSD and its main metabolite 2-oxo-3-hydroxy LSD (O-H-LSD) in serum and urine in emergency toxicological cases without time-consuming extraction steps. The method was developed on an ion-trap LC-MS/MS instrument coupled to a turbulent-flow extraction system. The validation data showed no significant matrix effects and no ion suppression has been observed in serum and urine. Mean intraday accuracy and precision for LSD were 101 and 6.84 %, in urine samples and 97.40 and 5.89 % in serum, respectively. For O-H-LSD, the respective values were 97.50 and 4.99 % in urine and 107 and 4.70 % in serum. Mean interday accuracy and precision for LSD were 100 and 8.26 % in urine and 101 and 6.56 % in serum, respectively. For O-H-LSD, the respective values were 101 and 8.11 % in urine and 99.8 and 8.35 % in serum, respectively. The lower limit of quantification for LSD was determined to be 0.1 ng/ml. LSD concentrations in serum were expected to be up to 8 ng/ml. 2-Oxo-3-hydroxy LSD concentrations in urine up to 250 ng/ml. The new method was accurate and precise in the range of expected serum and urine concentrations in patients with a suspected LSD intoxication. Until now, the method has been applied in five cases with suspected LSD intoxication where the intake of the drug has been verified four times with LSD concentrations in serum in the range of 1.80–14.70 ng/ml and once with a LSD concentration of 1.25 ng/ml in urine. In serum of two patients, the O-H-LSD concentration was determined to be 0.99 and 0.45 ng/ml. In the urine of a third patient, the O-H-LSD concentration was 9.70 ng/ml.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14(4):295–314

    Article  CAS  Google Scholar 

  2. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513–520

    Article  Google Scholar 

  3. Poch GK, Klette KL, Anderson C (2000) The quantitation of 2-oxo-3-hydroxy lysergic acid diethylamide (O-H-LSD) in human urine specimens, a metabolite of LSD: comparative analysis using liquid chromatography-selected ion monitoring mass spectrometry and liquid chromatography-ion trap mass spectrometry. J Anal Toxicol 24(3):170–179

    Article  CAS  Google Scholar 

  4. Poch GK, Klette KL, Hallare DA, Manglicmot MG, Czarny RJ, McWhorter LK, Anderson CJ (1999) Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. J Chromatogr B Biomed Sci Appl 724(1):23–33

    Article  CAS  Google Scholar 

  5. Chung A, Hudson J, McKay G (2009) Validated ultra-performance liquid chromatography-tandem mass spectrometry method for analyzing LSD, iso-LSD, nor-LSD, and O-H-LSD in blood and urine. J Anal Toxicol 33(5):253–259

    Article  CAS  Google Scholar 

  6. Klette KL, Horn CK, Stout PR, Anderson CJ (2002) LC-mS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions. J Anal Toxicol 26(4):193–200

    Article  CAS  Google Scholar 

  7. Li Z, McNally AJ, Wang H, Salamone SJ (1998) Stability study of LSD under various storage conditions. J Anal Toxicol 22(6):520–525

    Article  CAS  Google Scholar 

  8. Berg T, Jorgenrud B, Strand DH (2013) Determination of buprenorphine, fentanyl and LSD in whole blood by UPLC-MS-MS. J Anal Toxicol 37(3):159–165

    Article  CAS  Google Scholar 

  9. Canezin J, Cailleux A, Turcant A, Le Bouil A, Harry P, Allain P (2001) Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 765(1):15–27

    Article  CAS  Google Scholar 

  10. Johansen SS, Jensen JL (2005) Liquid chromatography-tandem mass spectrometry determination of LSD, ISO-LSD, and the main metabolite 2-oxo-3-hydroxy-LSD in forensic samples and application in a forensic case. J Chromatogr B Anal Technol Biomed Life Sci 825(1):21–28

    Article  CAS  Google Scholar 

  11. Musshoff F, Daldrup T (1997) Gas chromatographic/mass spectrometric determination of lysergic acid diethylamide (LSD) in serum samples. Forensic Sci Int 88(2):133–140

    Article  CAS  Google Scholar 

  12. Nelson CC, Foltz RL (1992) Determination of lysergic acid diethylamide (LSD), iso-LSD, and N-demethyl-LSD in body fluids by gas chromatography/tandem mass spectrometry. Anal Chem 64(14):1578–1585

    Article  CAS  Google Scholar 

  13. Favretto D, Frison G, Maietti S, Ferrara SD (2007) LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor. Int J Legal Med 121(4):259–265

    Article  Google Scholar 

  14. Caban M, Migowska N, Stepnowski P, Kwiatkowski M, Kumirska J (2012) Matrix effects and recovery calculations in analyses of pharmaceuticals based on the determination of β-blockers and β-agonists in environmental samples. J Chromatogr A 1258:117–127

    Article  CAS  Google Scholar 

  15. Dams R, Huestis MA, Lambert WE, Murphy CM (2003) Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom 14(11):1290–1294

    Article  CAS  Google Scholar 

  16. Mueller DM, Duretz B, Espourteille FA, Rentsch KM (2011) Development of a fully automated toxicological LC-MS(n) screening system in urine using online extraction with turbulent flow chromatography. Anal Bioanal Chem 400(1):89–100

    Article  CAS  Google Scholar 

  17. Aghajanian GK, Bing OH (1964) Persistence of lysergic acid diethylamide in plasma of human subjects. Clin Pharmacol Ther 5:611–614

    CAS  Google Scholar 

  18. Service USDoHaH (2001) Guidance for the industry—bioanalytical method validation

  19. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75(13):3019–3030

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by the Swiss Center for Applied Human Toxicology (to M.E.L.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katharina M. Rentsch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolder, P.C., Liechti, M.E. & Rentsch, K.M. Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. Anal Bioanal Chem 407, 1577–1584 (2015). https://doi.org/10.1007/s00216-014-8388-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-014-8388-1

Keywords

Navigation